X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA VENUS REMEDIES AJANTA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 28.3 -836.6 - View Chart
P/BV x 11.7 0.2 4,775.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AJANTA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
VENUS REMEDIES
Mar-16
AJANTA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,720218 789.0%   
Low Rs1,10382 1,343.5%   
Sales per share (Unadj.) Rs194.6365.6 53.2%  
Earnings per share (Unadj.) Rs45.21.5 3,043.0%  
Cash flow per share (Unadj.) Rs50.337.9 132.6%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0382.5 34.5%  
Shares outstanding (eoy) m88.7711.44 776.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.4 1,767.3%   
Avg P/E ratio x31.2101.0 30.9%  
P/CF ratio (eoy) x28.14.0 709.2%  
Price / Book Value ratio x10.70.4 2,725.4%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2991,717 7,299.4%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m2,570324 792.2%   
Avg. sales/employee Rs ThNM4,100.7-  
Avg. wages/employee Rs ThNM318.0-  
Avg. net profit/employee Rs ThNM16.7-  
INCOME DATA
Net Sales Rs m17,2754,183 413.0%  
Other income Rs m16620 827.4%   
Total revenues Rs m17,4424,203 415.0%   
Gross profit Rs m5,807812 715.5%  
Depreciation Rs m451417 108.1%   
Interest Rs m49380 12.9%   
Profit before tax Rs m5,47435 15,595.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,46018 8,065.7%   
Profit after tax Rs m4,01417 23,612.4%  
Gross profit margin %33.619.4 173.2%  
Effective tax rate %26.751.6 51.7%   
Net profit margin %23.20.4 5,717.0%  
BALANCE SHEET DATA
Current assets Rs m7,6392,771 275.7%   
Current liabilities Rs m2,7151,931 140.6%   
Net working cap to sales %28.520.1 142.0%  
Current ratio x2.81.4 196.1%  
Inventory Days Days43125 34.6%  
Debtors Days Days7954 146.4%  
Net fixed assets Rs m6,9145,328 129.8%   
Share capital Rs m177114 154.6%   
"Free" reserves Rs m11,4424,177 273.9%   
Net worth Rs m11,7214,376 267.8%   
Long term debt Rs m1491,911 7.8%   
Total assets Rs m14,8148,428 175.8%  
Interest coverage x112.91.1 10,338.8%   
Debt to equity ratio x00.4 2.9%  
Sales to assets ratio x1.20.5 235.0%   
Return on assets %27.44.7 582.5%  
Return on equity %34.20.4 8,816.4%  
Return on capital %46.56.6 705.1%  
Exports to sales %55.10-   
Imports to sales %6.020.5 29.3%   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038858 120.9%   
Fx inflow Rs m10,4220-   
Fx outflow Rs m1,678858 195.5%   
Net fx Rs m8,744-858 -1,018.7%   
CASH FLOW
From Operations Rs m3,264469 696.2%  
From Investments Rs m-2,09329 -7,167.5%  
From Financial Activity Rs m-1,186-464 255.8%  
Net Cashflow Rs m-1535 -42.9%  

Share Holding

Indian Promoters % 73.8 32.9 224.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.2 861.1%  
FIIs % 7.6 0.6 1,310.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 66.4 25.6%  
Shareholders   20,968 20,121 104.2%  
Pledged promoter(s) holding % 4.4 36.4 12.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS